Reaching the right audience is a critical decision. Use the system that does the work for you. Journals & Congresses helps you compare your options on the data points most important to you in making your decision. Get a ...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Gene therapy – affordability, access and reimbursement
Brian Huber, Vice President, Drug Development Services, considers the affordability, access and reimbursement challenges within the gene therapy market.
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
ICON issues financial guidance for 2022 as the CRO giant eyes spike in revenue growth
This article discusses ICON’s forecast revenues for 2022 and includes a statement from Steve Cutler on ICON’s successes from 2021.
-
The personalised medicine paradigm
Cindy Spittle shares insights on the growth of molecular diagnostic testing in clinical trials.
-
Sharing clinical trial results with paediatric participants
Kirsten Sherman Cervati contributes to this media article which discusses the considerations for returning results to paediatric participants.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
Capture, curate, consume: The three Cs of managing data in decentralised and hybrid clinical trials
Emily Mitchell, Executive Director, Decentralised Clinical Trials Operations and Christina Dinger, Director, Decentralised Clinical Trials Operations, run through some of the most important elements of collating and organising data during clinical trials.
This article was taken from Pharmafocus December 2021, pages 16-17. Samedan Ltd.
-
Combating antimicrobial resistance
Shelley McLendon, Vice President, Vaccines and Infectious Disease, discusses the use of novel diagnostics to help monitor for AMR outbreaks and reduce the overuse and misuse of antimicrobials.
-
The ecosystem overtakes the producers in pharma and life sciences
This article discusses the substantial number of significant acquisitions and mergers in the pharma and life sciences industry, and features ICON’s $12bn acquisition of PRA Health Sciences back in February.
